$RPID

RAPID MICRO BIOSYSTEMS, INC.

Rapid Micro Biosystems provides automation systems and services for microbial quality control testing in pharmaceutical manufacturing, including biologics, cell and gene therapies, vaccines and sterile injectables. Its main offering is the Growth Direct platform, which combines automated testing systems, proprietary consumables, software that connects with customers’ laboratory information management systems, and validation and support services. The platform automates sample handling, incubation and microbial detection and counting. Rapid Micro Biosystems sells Growth Direct systems and consumables, and earns recurring revenue from consumables and service contracts after systems are installed and validated. It sells directly through commercial and service teams in North America, Europe and the Asia-Pacific region, and also uses distributors. In February 2025, it granted MilliporeSigma global, co-exclusive distribution rights for certain products in industrial quality control applications. Rapid Micro Biosystems is headquartered in Lexington, Massachusetts.

10
0
3

No SEC Form 4 filings for $RPID in the last 30 days.

See all $RPID insider activity →
High

RAPID MICRO BIOSYSTEMS, INC. (RPID): Entry into a Material Definitive Agreement

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Rapid Micro Biosystems Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany LEXINGTON, Mass., November 16, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company prov

Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results • Reports third quarter 2026 total revenue of $9.5 million, representing 22% growth compared to the third quarter of 2025 ◦ Placed 7 Growth Direct systems and completed 12 validations in the third qu

RPID sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 13 news stories mentioning RPID (RAPID MICRO BIOSYSTEMS, INC.). Coverage has skewed bullish: 10 bullish, 0 neutral, and 3 bearish.

Recent RPID coverage spans earnings, financial news and corporate actions.

What's driving RPID

  • Deal terms and expected closing timeline create a clear takeover arbitrage setup for RPID, with upside tied to tender success and deal completion risk.

    SEC EDGAR 8-K · Nov 16, 2026

  • Earnings miss on both EPS and revenue likely reinforces weak demand and raises near-term downside risk for estimates.

    investing.com · Nov 16, 2026

  • Acquisition news is expected to lift the stock as investors price in a premium.

    SEC EDGAR 8-K · Nov 16, 2026

  • Deal terms likely anchor RPID toward the offer price, with volatility around tender-offer progress and closing conditions.

    tradingview.com · Nov 16, 2026

  • Guidance reaffirmation plus margin and recurring revenue growth supports a constructive near-term earnings trajectory, but cash burn and working-capital timing remain key risks.

    fool.com · Aug 14, 2026

AlphAI scores every news story that mentions RPID with an AI model for sentiment and relevance, and aggregates insider trades from RAPID MICRO BIOSYSTEMS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RPID

Score
$RPIDHighM&A· target · $0.75 · definitive

RAPID MICRO BIOSYSTEMS, INC. (RPID): Entry into a Material Definitive Agreement

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Rapid Micro Biosystems Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany LEXINGTON, Mass., November 16, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company prov

$RPIDHighEarnings

Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results • Reports third quarter 2026 total revenue of $9.5 million, representing 22% growth compared to the third quarter of 2025 ◦ Placed 7 Growth Direct systems and completed 12 validations in the third qu

$RPIDMedAI 8/10

Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call Transcript

Rapid Micro Biosystems (RPID) reported Q2 2026 revenue of $8.1M, up 10.9% YoY, with product revenue $5.3M and service revenue $2.8M. Recurring revenue was $5.0M, up 14.3% YoY, and gross margin was 15.0%. Net loss was $12.9M ($0.27/share). Full-year revenue guidance was reaffirmed at $37M to $41M.

Rapid Micro Biosystems Q2 Earnings Call Highlights

Rapid Micro Biosystems (NASDAQ: RPID) reported Q2 margin improvements, with consumables margins up 17 points YoY and service margin at a record 49%. Operating expenses rose to $13.5M. Net loss was $12.9M ($0.27/share). The company reaffirmed 2026 revenue guidance of $37M-$41M, raised validation targets, and projected Q3 revenue at least $9.5M.

Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

Rapid Micro Biosystems (Nasdaq: RPID) reported Q2 2026 total revenue of $8.1 million, up 11% year over year. Recurring revenue rose 14% to $5.0 million, 63% of total. Gross margin was a record 15%. The company reaffirmed 2026 revenue guidance of $37.0 million to $41.0 million and gross margin near 20%, and raised validation guidance to at least 27.

$RPIDMedEarnings

Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results

RAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results • Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 ◦ Achieved a significant milestone with the 200th Growth Direct system pla

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Sees Large Increase in Short Interest

Rapid Micro Biosystems (NASDAQ:RPID) experienced an 18.9% increase in short interest, reaching 377,502 shares as of March 31st, indicating a 1.4 days-to-cover ratio. This occurred despite recent insider selling by the COO and CFO, who disposed of shares worth over $73,000 in March. The company also reported missing EPS estimates but exceeded revenue expectations for the last quarter, with a current market capitalization of approximately $103.7 million.

Related tickers